MARKET

EYESW

EYESW

SECOND SIGHT MED
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.400
-0.090
-6.04%
Closed 16:00 04/16 EDT
OPEN
1.450
PREV CLOSE
1.490
HIGH
1.700
LOW
1.310
VOLUME
58.40K
TURNOVER
--
52 WEEK HIGH
6.29
52 WEEK LOW
0.0254
MARKET CAP
--
P/E (TTM)
-1.6560
1D
5D
1M
3M
1Y
5Y
BRIEF-Second Sight Medical Files Prospectus Relates To Offer, Sale From Time To Time By Selling Shareholders Up To 4.65 Mln Shares Of Co's Common Stock
reuters.com · 2d ago
BRIEF-Second Sight Medical Products Says Due To Appointment Of Dean Baker To Board & As Member Of Audit Committee, Nasdaq Determined Co Complies With Listing Rule
reuters.com · 04/08 10:10
BRIEF-Second Sight Medical Products Gave Notice To Pixium Of Termination Of MoU
reuters.com · 04/05 13:23
BRIEF-Second Sight Medical Products Inc Says Matthew Pfeffer Stepped Down As Acting CEO
reuters.com · 04/01 11:02
BRIEF-Second Sight Medical Products Announces Closing Of $27.9 Million Private Placement Of Common Stock
reuters.com · 03/26 21:19
BRIEF-Second Sight Medical Products Announces $27.9 Million Private Placement Of Common Stock
reuters.com · 03/24 11:29
BRIEF-Second Sight Medical Products Inc Announces Private Placement That Will Result In Gross Proceeds Of $27.9 Million
reuters.com · 03/24 10:13
BRIEF-Second Sight Medical Products Receives FDA Approval For The Argus 2S Retinal Prosthesis System
reuters.com · 03/05 13:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EYESW. Analyze the recent business situations of SECOND SIGHT MED through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.15%
Healthcare Equipment & Supplies
+0.17%
Key Executives
Chairman/Director
Gregg Williams
Chief Executive Officer
Scott Dunbar
Vice President - Operations
Ted Randolph
Vice President
Edward Randolph
Other
Stephen Okland
Director
Alexandra Larson
Director
Jonathan McGuire
Independent Director
Dean Baker
Independent Director
Aaron Mendelsohn
Independent Director
Matthew Pfeffer
No Data
  • All
  • Financials
  • Insiders
More
About EYESW
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company intends to develop Orion Visual Cortical Prosthesis which provides useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease or forms of cancer and trauma. Its product, The Argus II Retinal Prosthesis System (The Argus II) provides electrical stimulation of the retina to induce visual perception in blind individuals and helps in treating outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.

Webull offers kinds of Second Sight Medical Products Inc stock information, including NASDAQ:EYESW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYESW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EYESW stock methods without spending real money on the virtual paper trading platform.